Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sixth Seizure Of Indian Drugs Sparks UN Protest To Dutch

This article was originally published in PharmAsia News

Executive Summary

After the latest in a list of India-made generics drugs was seized in-transit by Dutch authorities, a United Nations group has joined the protest against the actions. The World Health Organization agency that buys drugs, UNITAID, complained after a load of HIV/AIDS drugs made by Aurobindo Pharma and headed for Nigeria was seized by the Netherlands. The shipment, bought by the Clinton Foundation on behalf of UNITAID, was the sixth reported incident of Indian generics being blocked in Europe while in transit to other markets. (Click here for more

You may also be interested in...

Indian Commerce Minister Speaks Strongly Against EU Drug Seizures

Recent seizures of Indian generic drugs bound for other destinations transiting through European ports are one of many attempts to discredit Indian generic drugs, visiting Indian Commerce & Industry Minister Anand Sharma told reporters in Washington on June 18 during a press briefing

Akorn Defaults On Loan Agreement After Sale Bid Falls Flat

Facing soaring legal costs stemming from its failed merger with Fresenius Kabi and burdened by substantial debt, Akorn elected to put itself up for sale earlier this year in order to help repay lenders. But the company has now defaulted on an agreement with its creditors after no bidder stepped up to the plate.

Pipeline Watch: Vericiguat, Evinacumab Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts